Congratulations to the WVU Clinical trials Research Unit (CTRU) and Dr. Adham Salkeni, WVU’s principal investigator for the NRG Oncology group, the largest clinical trials collaborative network in the United States. During the recent biannual meeting of the NRG, our CTRU was recognized as among the top ten main member sites to enroll the most patients on cancer clinical trials between January and June 2017. “This places WVU on the national map for clinical trials accrual,” Salkeni said. “This shows that we offer state-of-the-art research studies that examine the role of targeted therapies for the treatment of a wide variety of cancers that affect our patient population.”
The WVU Cancer Institute held its annual Pink Party event on Monday, September 10, to benefit Bonnie’s Bus, the mobile mammography unit that travels across West Virginia to provide mammograms to the women of the state.
WVU Cancer Institute offering groundbreaking treatment for gastroenteropancreatic neuroendocrine tumors
The WVU Cancer Institute is participating in the implementation of a new drug therapy for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of tumor that can form in the pancreas or in other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix. These life-threatening tumors can spread to other organs, such as the liver.
Meshea Poore, vice president for the Division of Diversity, Equity and Inclusion at WVU, will be the special guest at a Health Sciences Town Hall during WVU’s Diversity Week celebrations.